AU2023410055A1 - Antibodies targeting cd45 - Google Patents
Antibodies targeting cd45 Download PDFInfo
- Publication number
- AU2023410055A1 AU2023410055A1 AU2023410055A AU2023410055A AU2023410055A1 AU 2023410055 A1 AU2023410055 A1 AU 2023410055A1 AU 2023410055 A AU2023410055 A AU 2023410055A AU 2023410055 A AU2023410055 A AU 2023410055A AU 2023410055 A1 AU2023410055 A1 AU 2023410055A1
- Authority
- AU
- Australia
- Prior art keywords
- antibodies targeting
- targeting
- antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Transplantation (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Hematology (AREA)
- Oncology (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22216653 | 2022-12-23 | ||
| EP22216653.0 | 2022-12-23 | ||
| EP23188447.9 | 2023-07-28 | ||
| EP23188447 | 2023-07-28 | ||
| PCT/EP2023/087612 WO2024133890A1 (en) | 2022-12-23 | 2023-12-22 | Antibodies targeting cd45 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2023410055A1 true AU2023410055A1 (en) | 2025-05-29 |
Family
ID=89541990
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2023410055A Pending AU2023410055A1 (en) | 2022-12-23 | 2023-12-22 | Antibodies targeting cd45 |
Country Status (6)
| Country | Link |
|---|---|
| KR (1) | KR20250122457A (en) |
| CN (1) | CN120476145A (en) |
| AU (1) | AU2023410055A1 (en) |
| IL (1) | IL321599A (en) |
| MX (1) | MX2025007213A (en) |
| WO (1) | WO2024133890A1 (en) |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| DK0985039T3 (en) | 1997-06-12 | 2008-06-09 | Novartis Int Pharm Ltd | Artificial antibody polypeptides |
| US20170226209A1 (en) | 2014-08-01 | 2017-08-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | An anti-cd45rc antibody for use as drug |
| GB201601073D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies |
| CA3016901C (en) | 2016-03-07 | 2023-06-13 | Actinium Pharmaceuticals, Inc. | Stabilized radiolabeled anti-cd45 immunoglobulin compositions |
| US20200308280A1 (en) | 2017-10-25 | 2020-10-01 | Actinium Pharmaceuticals, Inc. | Methods for cancer treatment using a radiolabeled anti-cd45 immunoglobulin and adoptive cell therapies |
| EP3498293A1 (en) | 2017-12-15 | 2019-06-19 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Treatment of monogenic diseases with an anti-cd45rc antibody |
| CN109991410B (en) | 2017-12-29 | 2022-07-05 | 上海白泽医学检验所有限公司 | A kind of composition containing anti-CD45 monoclonal antibody and using method thereof |
| WO2020018580A1 (en) | 2018-07-16 | 2020-01-23 | Fred Hutchinson Cancer Research Center | Bispecific affinity reagent and related methods for pretargeted radioimmunotherapy against cd45+ cell |
| EP3626265A1 (en) | 2018-09-21 | 2020-03-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-human cd45rc antibodies and uses thereof |
| EP3877416A4 (en) * | 2018-10-30 | 2022-07-27 | Magenta Therapeutics, Inc. | ANTI-CD45 ANTIBODIES AND CONJUGATES THEREOF |
| EP3917313A4 (en) | 2019-02-01 | 2023-02-08 | Actinium Pharmaceuticals, Inc. | Molecules and their derivatives directed against cd45 |
| EP3927361A4 (en) | 2019-02-21 | 2022-11-30 | Ramot at Tel-Aviv University Ltd. | Treatment of diseases with multimeric peptides |
| EP3958910A4 (en) | 2019-04-24 | 2023-08-02 | Magenta Therapeutics, Inc. | Anti-cd45 antibody drug conjugates and uses thereof |
| KR20220091567A (en) * | 2019-11-01 | 2022-06-30 | 마젠타 테라퓨틱스 인코포레이티드 | Anti-CD45 Antibodies and Conjugates Thereof |
-
2023
- 2023-12-22 AU AU2023410055A patent/AU2023410055A1/en active Pending
- 2023-12-22 WO PCT/EP2023/087612 patent/WO2024133890A1/en active Pending
- 2023-12-22 KR KR1020257017579A patent/KR20250122457A/en active Pending
- 2023-12-22 CN CN202380088284.1A patent/CN120476145A/en active Pending
-
2025
- 2025-06-18 IL IL321599A patent/IL321599A/en unknown
- 2025-06-19 MX MX2025007213A patent/MX2025007213A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL321599A (en) | 2025-08-01 |
| WO2024133890A1 (en) | 2024-06-27 |
| KR20250122457A (en) | 2025-08-13 |
| CN120476145A (en) | 2025-08-12 |
| MX2025007213A (en) | 2025-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4217396A4 (en) | Novel anti-claudin18 antibodies | |
| EP4324925A4 (en) | Anti-c1s antibody | |
| AU2023410055A1 (en) | Antibodies targeting cd45 | |
| HK40120094A (en) | Antibodies targeting cd117 | |
| HK40111251A (en) | Antibodies targeting ccr2 | |
| HK40113201A (en) | Novel anti-lag3 antibodies | |
| HK40116221A (en) | Novel anti-il-36r antibodies | |
| HK40112319A (en) | Novel anti-sirpa antibodies | |
| HK40106257A (en) | Novel anti-sirpa antibodies | |
| HK40105878A (en) | Novel anti-masp-2 antibodies | |
| HK40104244A (en) | Novel anti-hvegfr2 antibodies | |
| HK40115462A (en) | Anti-par2 antibodies | |
| HK40093421A (en) | Novel anti-gremlin1 antibodies | |
| HK40110366A (en) | Galectin-10 antibodies | |
| HK40115074A (en) | Galectin-10 antibodies | |
| AU2022902836A0 (en) | SARS-CoV-2 antibodies | |
| AU2022902742A0 (en) | Anti-CCR8 antibodies | |
| HK40097196A (en) | Novel anti-cldn18 antibodies | |
| HK40097043A (en) | Novel anti-claudin18 antibodies | |
| HK40116629A (en) | Anti-abcb1 antibodies | |
| HK40105906A (en) | Anti-hla-g antibodies | |
| HK40081039A (en) | Novel antibodies | |
| HK40110514A (en) | Anti-csp antibodies | |
| HK40102548A (en) | Anti-sirp-alpha antibodies | |
| HK40109728A (en) | Anti-trem-1 antibodies |